Denali Therapeutics Inc. (DNLI) Misses Q1 EPS by 9c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q1 EPS of ($0.80), $0.09 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $35.14 million versus the consensus estimate of $26.88 million.

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
• Ardent Health revises 2025 non-GAAP figures after SEC staff talks